AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT105.23-0.29 (-0.27%) ▼|ACN175.80-3.23 (-1.80%) ▼|ADBE254.86-2.40 (-0.93%) ▼|AMAT468.85-3.94 (-0.83%) ▼|AMD521.10+15.36 (+3.04%) ▲|AMGN391.27-1.90 (-0.48%) ▼|AMT175.43-0.30 (-0.17%) ▼|AMZN252.40-4.57 (-1.78%) ▼|AVGO364.38-4.18 (-1.13%) ▼|AXP321.80-4.30 (-1.32%) ▼|BA206.42-4.31 (-2.05%) ▼|BAC62.67+0.28 (+0.45%) ▲|BKNG173.43-6.87 (-3.81%) ▼|BLK1,072.03-23.34 (-2.13%) ▼|BMY64.41-0.28 (-0.43%) ▼|BNY162.51-0.34 (-0.21%) ▼|BRK-B506.72+0.89 (+0.18%) ▲|C137.80+1.06 (+0.78%) ▲|CAT815.56-6.92 (-0.84%) ▼|CL88.03-0.38 (-0.43%) ▼|CMCSA24.59-1.74 (-6.61%) ▼|COF210.86-3.10 (-1.45%) ▼|COP136.53+1.49 (+1.10%) ▲|COST902.60-7.58 (-0.83%) ▼|CRM244.16-4.96 (-1.99%) ▼|CSCO109.43+0.26 (+0.24%) ▲|CVS95.38-0.69 (-0.72%) ▼|CVX213.81+4.01 (+1.91%) ▲|DE677.21-3.52 (-0.52%) ▼|DHR204.85-0.38 (-0.19%) ▼|DIS104.18-0.88 (-0.84%) ▼|DUK120.43-0.81 (-0.67%) ▼|EMR150.34-1.81 (-1.19%) ▼|FDX309.19-4.94 (-1.57%) ▼|GD352.67-3.91 (-1.10%) ▼|GE325.42-9.49 (-2.83%) ▼|GEV951.04-20.27 (-2.09%) ▼|GILD145.65-0.99 (-0.68%) ▼|GM83.76-2.03 (-2.37%) ▼|GOOG328.38-7.00 (-2.09%) ▼|GOOGL330.65-7.71 (-2.28%) ▼|GS1,028.78-7.75 (-0.75%) ▼|HD310.45-3.25 (-1.04%) ▼|HON204.93-3.31 (-1.59%) ▼|IBM239.94+7.85 (+3.38%) ▲|INTC106.24+1.77 (+1.69%) ▲|INTU313.94-4.99 (-1.56%) ▼|ISRG353.24+3.08 (+0.88%) ▲|JNJ267.08-2.04 (-0.76%) ▼|JPM354.71+1.20 (+0.34%) ▲|KO87.55-0.81 (-0.92%) ▼|LIN466.65-1.73 (-0.37%) ▼|LLY1,124.21+0.30 (+0.03%) ▲|LMT524.46-11.69 (-2.18%) ▼|LOW198.60-2.20 (-1.10%) ▼|LRCX315.84-4.58 (-1.43%) ▼|MA567.50-3.39 (-0.59%) ▼|MCD253.48-2.33 (-0.91%) ▼|MDLZ62.42+0.79 (+1.28%) ▲|MDT91.89-0.50 (-0.54%) ▼|META653.69+40.21 (+6.55%) ▲|MMM164.40-3.12 (-1.86%) ▼|MO67.89-0.28 (-0.41%) ▼|MRK147.53-0.93 (-0.63%) ▼|MS215.35-0.89 (-0.41%) ▼|MSFT491.65-2.30 (-0.47%) ▼|MU1,027.77+27.51 (+2.75%) ▲|NEE82.65-1.18 (-1.41%) ▼|NFLX76.03-0.74 (-0.96%) ▼|NKE37.35-0.75 (-1.97%) ▼|NOW131.11-3.10 (-2.31%) ▼|NVDA223.67-2.06 (-0.91%) ▼|ORCL161.63-0.89 (-0.55%) ▼|PEP136.69-1.76 (-1.27%) ▼|PFE27.78-0.01 (-0.04%) ▼|PG142.64-2.94 (-2.02%) ▼|PLTR169.53-0.77 (-0.45%) ▼|PM185.71+0.98 (+0.53%) ▲|QCOM176.40+2.31 (+1.33%) ▲|RTX197.55-1.26 (-0.63%) ▼|SBUX100.04-1.97 (-1.93%) ▼|SCHW106.54-0.33 (-0.31%) ▼|SO88.34-0.65 (-0.73%) ▼|SPG204.53-5.10 (-2.43%) ▼|T25.15-0.45 (-1.76%) ▼|TMO605.69+2.67 (+0.44%) ▲|TMUS177.34-4.35 (-2.39%) ▼|TSLA367.81-0.35 (-0.10%) ▼|TXN261.59+2.67 (+1.03%) ▲|UBER71.08-2.05 (-2.80%) ▼|UNH393.06-7.78 (-1.94%) ▼|UNP284.74-3.71 (-1.29%) ▼|UPS99.22-1.26 (-1.25%) ▼|USB62.11-0.38 (-0.61%) ▼|V367.39-1.25 (-0.34%) ▼|VZ49.74-0.67 (-1.33%) ▼|WFC89.67+1.71 (+1.94%) ▲|WMT105.83-0.22 (-0.21%) ▼|XOM164.23+3.57 (+2.22%) ▲|AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT105.23-0.29 (-0.27%) ▼|ACN175.80-3.23 (-1.80%) ▼|ADBE254.86-2.40 (-0.93%) ▼|AMAT468.85-3.94 (-0.83%) ▼|AMD521.10+15.36 (+3.04%) ▲|AMGN391.27-1.90 (-0.48%) ▼|AMT175.43-0.30 (-0.17%) ▼|AMZN252.40-4.57 (-1.78%) ▼|AVGO364.38-4.18 (-1.13%) ▼|AXP321.80-4.30 (-1.32%) ▼|BA206.42-4.31 (-2.05%) ▼|BAC62.67+0.28 (+0.45%) ▲|BKNG173.43-6.87 (-3.81%) ▼|BLK1,072.03-23.34 (-2.13%) ▼|BMY64.41-0.28 (-0.43%) ▼|BNY162.51-0.34 (-0.21%) ▼|BRK-B506.72+0.89 (+0.18%) ▲|C137.80+1.06 (+0.78%) ▲|CAT815.56-6.92 (-0.84%) ▼|CL88.03-0.38 (-0.43%) ▼|CMCSA24.59-1.74 (-6.61%) ▼|COF210.86-3.10 (-1.45%) ▼|COP136.53+1.49 (+1.10%) ▲|COST902.60-7.58 (-0.83%) ▼|CRM244.16-4.96 (-1.99%) ▼|CSCO109.43+0.26 (+0.24%) ▲|CVS95.38-0.69 (-0.72%) ▼|CVX213.81+4.01 (+1.91%) ▲|DE677.21-3.52 (-0.52%) ▼|DHR204.85-0.38 (-0.19%) ▼|DIS104.18-0.88 (-0.84%) ▼|DUK120.43-0.81 (-0.67%) ▼|EMR150.34-1.81 (-1.19%) ▼|FDX309.19-4.94 (-1.57%) ▼|GD352.67-3.91 (-1.10%) ▼|GE325.42-9.49 (-2.83%) ▼|GEV951.04-20.27 (-2.09%) ▼|GILD145.65-0.99 (-0.68%) ▼|GM83.76-2.03 (-2.37%) ▼|GOOG328.38-7.00 (-2.09%) ▼|GOOGL330.65-7.71 (-2.28%) ▼|GS1,028.78-7.75 (-0.75%) ▼|HD310.45-3.25 (-1.04%) ▼|HON204.93-3.31 (-1.59%) ▼|IBM239.94+7.85 (+3.38%) ▲|INTC106.24+1.77 (+1.69%) ▲|INTU313.94-4.99 (-1.56%) ▼|ISRG353.24+3.08 (+0.88%) ▲|JNJ267.08-2.04 (-0.76%) ▼|JPM354.71+1.20 (+0.34%) ▲|KO87.55-0.81 (-0.92%) ▼|LIN466.65-1.73 (-0.37%) ▼|LLY1,124.21+0.30 (+0.03%) ▲|LMT524.46-11.69 (-2.18%) ▼|LOW198.60-2.20 (-1.10%) ▼|LRCX315.84-4.58 (-1.43%) ▼|MA567.50-3.39 (-0.59%) ▼|MCD253.48-2.33 (-0.91%) ▼|MDLZ62.42+0.79 (+1.28%) ▲|MDT91.89-0.50 (-0.54%) ▼|META653.69+40.21 (+6.55%) ▲|MMM164.40-3.12 (-1.86%) ▼|MO67.89-0.28 (-0.41%) ▼|MRK147.53-0.93 (-0.63%) ▼|MS215.35-0.89 (-0.41%) ▼|MSFT491.65-2.30 (-0.47%) ▼|MU1,027.77+27.51 (+2.75%) ▲|NEE82.65-1.18 (-1.41%) ▼|NFLX76.03-0.74 (-0.96%) ▼|NKE37.35-0.75 (-1.97%) ▼|NOW131.11-3.10 (-2.31%) ▼|NVDA223.67-2.06 (-0.91%) ▼|ORCL161.63-0.89 (-0.55%) ▼|PEP136.69-1.76 (-1.27%) ▼|PFE27.78-0.01 (-0.04%) ▼|PG142.64-2.94 (-2.02%) ▼|PLTR169.53-0.77 (-0.45%) ▼|PM185.71+0.98 (+0.53%) ▲|QCOM176.40+2.31 (+1.33%) ▲|RTX197.55-1.26 (-0.63%) ▼|SBUX100.04-1.97 (-1.93%) ▼|SCHW106.54-0.33 (-0.31%) ▼|SO88.34-0.65 (-0.73%) ▼|SPG204.53-5.10 (-2.43%) ▼|T25.15-0.45 (-1.76%) ▼|TMO605.69+2.67 (+0.44%) ▲|TMUS177.34-4.35 (-2.39%) ▼|TSLA367.81-0.35 (-0.10%) ▼|TXN261.59+2.67 (+1.03%) ▲|UBER71.08-2.05 (-2.80%) ▼|UNH393.06-7.78 (-1.94%) ▼|UNP284.74-3.71 (-1.29%) ▼|UPS99.22-1.26 (-1.25%) ▼|USB62.11-0.38 (-0.61%) ▼|V367.39-1.25 (-0.34%) ▼|VZ49.74-0.67 (-1.33%) ▼|WFC89.67+1.71 (+1.94%) ▲|WMT105.83-0.22 (-0.21%) ▼|XOM164.23+3.57 (+2.22%) ▲|
22.7 C
New York
Thursday, September 10, 2026

Tag: metabolism

newssourceFORcompanyinformationcontent1releasesmarket

Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

OIKOS® Launches First-of-Its-Kind Cultured Dairy Drink Featuring A Patented Blend of Nutrients Designed to Help Build & Retain Muscle Mass During Weight Loss

New OIKOS FUSION™ is the first product in the yogurt category with a proprietary combination of whey, leucine and vitamin D designed to support...

KeySlim Drops Explores Ingredient-First Weight Management Trends in 2025

A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals 
A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals

2025 Report: “PurDentix Reviews and Complaints” Surge Reflects Growing Curiosity Around Oral Microbiome Supplements

Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025 
Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025

XORTX Completes USD $114,500 Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

THC Gummies Launch in 2025: Delta-9, Sleep, and CBD Hybrid Editions

Exhale Wellness introduces new THC gummies in 2025, including Delta-9, Sleep, and CBD hybrid options for flavor, balance, and targeted cannabinoid support. 
 Exhale Wellness introduces new THC gummies in 2025, including Delta-9, Sleep, and CBD hybrid options for flavor, balance, and targeted cannabinoid support.

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

LIVN Nutrition Launches First-Ever HMB Fruit Chews, Introducing a New Delivery Format to Support “Musclespan” and Healthy Aging

SAN DIEGO, Aug. 5, 2025 /PRNewswire/ -- LIVN Nutrition today announced the launch of its groundbreaking HMB Fruit Chews, the first chewable format to deliver...

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.

Sciaticyl’s “Nerve Reset” Discovery Sparks 2025 Surge in Sciatica Support Solutions Across U.S.

A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort. 
A powerful surge in online searches for natural sciatica remedies has thrust Sciaticyl into the spotlight, thanks to a peculiar “nerve reset” approach linked to ancient herbal wisdom and modern neuroscience. This unique formulation blends 11 ingredients—including Bacopa Monnieri, Alpha Lipoic Acid, and key nerve-regenerating compounds—positioning Sciaticyl as a leading curiosity point for those seeking non-surgical options. As nerve pain awareness grows in 2025, researchers and consumers alike are exploring how nutritional support may play a role in long-term sciatica recovery, vitality, and freedom from discomfort.

2025 Report: “ProZenith Reviews and Complaints” Search Surge Mirrors Interest in Clean Energy Supplements

Increased search volume around clean-label metabolic supplements — including queries like “ProZenith complaints” — reflects a wider shift in how consumers are navigating stimulant-free wellness solutions in North America. 
Increased search volume around clean-label metabolic supplements — including queries like “ProZenith complaints” — reflects a wider shift in how consumers are navigating stimulant-free wellness solutions in North America.

Exhale Wellness Recognized as the #1 Delta 9 THC Gummies by Onpattison

Exhale Wellness earns top spot for best Delta 9 gummies in 2025, recognized for quality, transparency, and customer satisfaction by Onpattison. 
Exhale Wellness earns top spot for best Delta 9 gummies in 2025, recognized for quality, transparency, and customer satisfaction by Onpattison.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMetabolism

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers